PUBLISHER: The Business Research Company | PRODUCT CODE: 1250845
PUBLISHER: The Business Research Company | PRODUCT CODE: 1250845
“Peptide Therapeutics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on peptide therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for peptide therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The peptide therapeutics market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the peptide therapeutics market are: Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Sanofi, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Bachem Holding AG, Takeda Pharmaceutical Company Limited, Galena Biopharmaceuticals, Arch Biopartners, Arch Biopartners Inc., Novo Nordisk A/S, Circle Pharma Inc., and Corden Pharma GmbH.
The global peptide therapeutics market grew from $37.26 billion in 2022 to $40.7 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peptide therapeutics market is expected to grow to $58.75 billion in 2027 at a CAGR of 9.6%.
The peptide therapeutics market includes revenues earned by entities by creating drugs to treat a variety of diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
Peptide therapeutics refer to a therapeutic approach that uses peptides as medications. Peptides are a distinct family of pharmacological substances that are molecularly situated in between proteins and tiny molecules. Peptides that are found in nature serve a variety of purposes, including those of hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives. Consequently, using peptides as treatments offers a way to target a variety of cells and control their response.
North America was the largest region in the peptide therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of peptide therapeutics are generic and branded. The branded peptide therapeutics are drugs sold under the brand names of large pharma companies that own the patent for these drugs. These are more expensive than generic drugs as they maintain a distinct brand. The peptide therapeutics are administered in several routes such as parenteral, mucosal, oral, and transdermal. They are used for treating cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, haematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, and acromegaly.
An increase in the prevalence of chronic diseases is expected to propel the growth of the peptide therapeutics market. Chronic diseases are long-lasting sickness that often cannot be healed, however, it is occasionally curable and controllable. Chronic diseases are increasing due to increasing use to tobacco products, poor nutrition, physical inactivity, excessive use of alcohol and others. The use of peptide therapeutics aids in the prevention and treatment of certain chronic diseases. For instance, in 2020, according to the American Hospital Association (AHA), the national organization that represents and serves all types of hospitals and health care networks and their patients and communities, 157 million Americans were affected by chronic diseases in 2020, and it is estimated to reach 171 million by 2030. Therefore, the increase in the prevalence of chronic diseases is expected to drive the peptide therapeutics market during the forecast period.
Technological advancement is a key trend in the peptide therapeutics market. The companies operating in peptide therapeutics are utilizing advanced technologies such as artificial intelligence is to attain higher efficiency in drug development. For instance, in April 2020, Nuratis, an Ireland-based biotech company is utilizing artificial intelligence (AI) technologies to discover therapeutic peptides, extended its research into possible remedies for COVID-19 symptoms. Nuritas employed its AI platform to find peptides that are effective against COVID-19 targets. It took two initiatives to identify COVID-19 peptides: one for antiviral peptides that target how SARS-CoV-2 hijacks cells and the other for peptides that locally lower lung inflammation without inhibiting the immune system as a whole.
In August 2021, Bayer, a Germany-based pharmaceutical company acquired Vividion Therapeutics for an undisclosed amount. Through this acquisition, Bayer will improve its small molecule expertise and reach new markets. The addition of a cutting-edge chemoproteomics platform will improve Bayer's drug discovery capabilities. Vividion Therapeutics, Inc., is a US-based biotechnology company focused on transforming the future of human health by creating highly selective small-molecule medicines that drug traditionally inaccessible targets.
The countries covered in the peptide therapeutics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The peptide therapeutics market research report is one of a series of new reports from The Business Research Company that provides peptide therapeutics market statistics, including peptide therapeutics industry global market size, regional shares, competitors with a peptide therapeutics market share, detailed peptide therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics industry. This peptide therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.